Connect with us


Sensyne Health signs strategic agreement with Wolverhampton NHS

Avatar photo



The agreement will help boost research into sector like AI and patient care

Sensyne Health has signed a five-year non-exclusive strategic research agreement with The Royal Wolverhampton NHS Trust (RWT).

The agreement will enable the application of clinical AI research to improve patient care and accelerate research into new medicines.

The RWT dataset covers 700,000 unique patient records from a patient population of approximately 470,000 people. The new SRA brings the combined total of anonymised data available for analysis by Sensyne to 6.8 million patients.

The trust will receive 1,428,571 ordinary shares in Sensyne Health, representing 0.9% of the existing issued share capital of Sensyne. This brings the total share ownership held by NHS trusts in Sensyne to 12.6%.

RWT will also receive from Sensyne an investment of up to £250,000 per year over the 5-year term of the contract for specific investments in NHS information technology to enable the curation and analysis of data under the SRA.

Sultan Mahmud, chief innovation, integration and research officer at RWT, said: “We are delighted to announce a partnership with Sensyne Health. Their model of collaboration with the NHS and active investment into the NHS is a unique one.

“Sensyne are currently working with several leading NHS foundation trusts and joining this community of practice enhances our ability to test new and innovative ways to use data to drive care processes and contribute to vital health research.

“In this collaboration we will focus on improving prevention, early diagnosis and treatment of illnesses for complex patients so that we can provide anticipatory care. Our clinical teams and informatics colleagues are looking forward to working with Sensyne.”

Lord Paul Drayson, CEO of Sensyne Health, added: “The SRA continues Sensyne’s momentum in expanding its anonymised patient data set and deepening the diversity of the therapeutic areas within it. This in turn helps provide Sensyne with the critical mass of data to improve patient care and accelerate medical research.”

The financial return RWT receives from Sensyne will be reinvested back into the NHS to fund patient care.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories